Program
pumitamig
Also written as “Pumitamig”, “PM8002” and “BNT327”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Breast Neoplasms · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTech | 2321 open or running | phase 3since May 14, 2024 | Feb 15, 2023 | Jan 1, 2027phase 2 · NCT05879055 |
| Bristol-Myers Squibb | 99 open or running | phase 3since Oct 23, 2025 | Sep 26, 2024 | Mar 15, 2028phase 2 · NCT07871214 |
| Boehringer Ingelheim | 11 open or running | phase 2since Sep 22, 2026 | Sep 22, 2026 | Apr 17, 2030phase 2 · NCT07843940 |
| DualityBio | 11 open or running | phase 2since Apr 9, 2025 | Apr 9, 2025 | Jun 30, 2030phase 2 · NCT06953089 |
- Named in Bristol-Myers Squibb’s own pipeline as
pumitamig
, phase 3, as of Oct 29, 2026 (source).
Also a collaborator on its studies: MediLink Therapeutics (Suzhou), biontech-shanghai-pharmaceuticals-co-ltd and Genmab.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentBristol Myers Squibb develops it with BioNTech, worldwide, profits and losses shared equally.Announced Jun 2, 2025 · Source: BioNTech, Jun 2, 2025
How Boehringer Ingelheim and DualityBio relate to it is not in the registry or these sources.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Feb 15, 2023.
- Mar 19, 2025Phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06892548 · 594 planned · United States, Australia, China and more
- Apr 9, 2025DualityBio's first study: phase 2 study in Squamous Cell Carcinoma of Head and NeckNew to DualityBioDualityBio · NCT06953089 · 750 planned · United States, Australia, China and more
- Jul 3, 20252 phase 2 studiesBioNTech · NCT07070232, NCT07079631
- Aug 1, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungBioNTech · NCT07111520 · 880 planned · United States, Australia, China and more
- Sep 8, 2025Phase 3 study in Breast NeoplasmsBioNTech · NCT07173751 · 558 planned · United States, Argentina, Australia and more
- Oct 23, 20252 phase 3 studiesBristol-Myers Squibb · NCT07221357, NCT07221149
- Dec 9, 2025Phase 2 study in GlioblastomaBioNTech · NCT07297212 · 75 planned · China
- Dec 17, 20252 phase 2 studiesBristol-Myers Squibb · NCT07293351, NCT07291076
- Jan 21, 20262 phase 3 studies in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07361510, NCT07361497
- Jun 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07680764 · 160 planned · United States, Argentina, Australia and more
- Sep 22, 2026Boehringer Ingelheim's first study: phase 2 study in Small Cell Lung CarcinomaNew to Boehringer IngelheimBoehringer Ingelheim · NCT07843940 · 55 planned · United States, Australia, Belgium and more
- Oct 7, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT07871214 · 80 planned · United States, Australia, Canada and more
- Oct 14, 2026Primary completion moved from 2028-12 to 2029-04Date moved laterphase 3 · +4 months · NCT06712355
- Oct 22, 2026Primary completion moved from 2027-01-25 to 2027-05Date moved laterphase 3 · +4 months · NCT06616532
Ahead
- Jan 1, 2027Primary completion: phase 2 study in Neuroendocrine TumorsBioNTech · NCT05879055
- May 2027Primary completion: phase 3 study in SCLCBioNTech · NCT06616532
- Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaBioNTech · NCT06449209
- Jul 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsBioNTech · NCT06419621
TargetBeta
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon adm…”NCIt, read by Claude
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07871214Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Not yet recruiting | Bristol-Myers Squibb | Mar 15, 2028 | 80 |
| NCT07843940Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 2 | Recruiting | Boehringer Ingelheim | Apr 17, 2030 | 55 |
| NCT07680764Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Recruiting | Bristol-Myers Squibb | Sep 15, 2028 | 160 |
| NCT07361510Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Oct 14, 2031 | 750 |
| NCT07361497Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Sep 18, 2030 | 850 |
| NCT07293351Carcinoma, Renal Cell · United States, Argentina, Australia and more | 2 | Recruiting | Bristol-Myers Squibb | Nov 28, 2029 | 474 |
| NCT07291076Carcinoma, Hepatocellular · United States, Australia, Chile and more | 2 | Recruiting | Bristol-Myers Squibb | Oct 15, 2029 | 198 |
| NCT07297212Glioblastoma · China | 2 | Recruiting | BioNTech | Jan 2028 | 75 |
| NCT07221357Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Feb 2, 2030 | 990 |
| NCT07221149Stomach Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Bristol-Myers Squibb | Nov 8, 2030 | 690 |
| NCT07173751Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | BioNTech | Dec 2029 | 558 |
| NCT07111520Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more | 2 | Recruiting | BioNTech | Nov 2028 | 880 |
| NCT07079631Colorectal Neoplasms · United States, Germany, Japan and more | 2 | Recruiting | BioNTech | Dec 2030 | 482 |
| NCT07070232Lethal Congenital Contracture Syndrome 2 · United States, Australia, Belgium and more | 2 | Recruiting | BioNTech | Mar 2028 | 1,438 |
| NCT06953089Squamous Cell Carcinoma of Head and Neck · United States, Australia, China and more | 2 | Recruiting | DualityBio | Jun 30, 2030 | 750 |
| NCT06892548Small Cell Lung Carcinoma · United States, Australia, China and more | 2 | Recruiting | BioNTech | Sep 2028 | 594 |
| NCT06841055Carcinoma, Non-Small-Cell Lung · United States, Australia, South Korea and more | 2 | Recruiting | BioNTech | Oct 2028 | 60 |
| NCT06827236Breast Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | BioNTech | Aug 2029 | 380 |
| NCT06712355Small Cell Lung Carcinoma · United States, Australia, China and more | 3 | Recruiting | BioNTech | Apr 2029 | 621 |
| NCT06712316Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | BioNTech | Jan 2029 | 1,580 |
| NCT06618287Lung Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Bristol-Myers Squibb | Feb 26, 2031 | 416 |
| NCT06616532SCLC · China | 3 | Active, not recruiting | BioNTech | May 2027 | 404 |
| NCT06584071Liver Neoplasms | 2 | Not yet recruiting | BioNTech | Oct 2026 | 140 |
| NCT06449222Triple Negative Breast Neoplasms · United States, Australia, Turkey (Türkiye) and more | 2 | Active, not recruiting | BioNTech | Aug 2028 | 83 |
| NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more | 2 | Active, not recruiting | BioNTech | Jun 2027 | 110 |
| NCT06419621Triple Negative Breast Neoplasms · China | 3 | Active, not recruiting | BioNTech | Jul 2027 | 392 |
| NCT05918133TNBC · China | 2 | Active, not recruiting | BioNTech | Oct 30, 2026 | 42 |
| NCT05918107MPM · China | 2 | Completed | BioNTech | Mar 31, 2026 | 31 |
| NCT05918445Neoplasms · China | 2 | Recruiting | BioNTech | Nov 30, 2025 | 380 |
| NCT05879068SCLC · China | 2 | Active, not recruiting | BioNTech | Apr 30, 2025 | 99 |
| NCT05879055Neuroendocrine Tumors · China | 2 | Active, not recruiting | BioNTech | Jan 1, 2027 | 31 |
| NCT05864105Carcinoma, Hepatocellular · China | 2 | Completed | BioNTech | Jul 24, 2025 | 35 |
| NCT05844150SCLC · China | 2 | Active, not recruiting | BioNTech | May 10, 2024 | 50 |
| NCT05756972NSCLC · China | 2 | Active, not recruiting | BioNTech | Sep 13, 2024 | 64 |
How it is read
Names in the registry
- “Pumitamig”, 18 entries
- “PM8002”, 11 entries
- “BNT327”, 3 entries
- “BNT327 Dose Level 1 (DL1)”, 2 entries
- “BNT327 Dose Level 2 (DL2)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Small Cell Lung Carcinoma, 4 studies
- Breast Neoplasms, 2 studies
- Carcinoma, Hepatocellular, 2 studies
- Colorectal Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.